Relationship between diabetic retinopathy microalbuminuria and other modifiable risk factors

Chawla, Shubhaa; Trehan, Siddhant; Chawla, Aastha; Jaggi, Shalini; Chawla, Rajeev; Kumar, Vinay; Singh, Deependra Vikram

doi:10.1016/j.pcd.2021.01.012

Cited by 9 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microalbuminuria was associated crosssectionally with the presence of retinopathy in patients with T2DM. This study suggests that microalbuminuria may be a marker for the risk of proliferative retinopathy development 453 . Recent studies have also started shedding light on the association of dyslipidemia with DR. 454 Implementations A sufficient number of trained general ophthalmologists and general physicians are required to develop an integrated DR model that facilitates early detection and create awareness of DR. Medical camps should be conducted for screening of diabetes and retinopathy, which will help to identify people at risk of sight-threatening DR and initiate treatment including laser photocoagulation or vitreous surgery.…”

Section: Evidencementioning

confidence: 60%

RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022

2022

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Section: Evidencementioning

confidence: 60%

RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022

2022

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

“…When the duration of type 2 diabetes reaches 9.4 ± 6.0 (mean ± SD) years, patients may have retinopathy. Therefore, we should always emphasize the early diagnosis and treatment of diabetic retinopathy in diabetic patients ( 53 ). It is worth noting that most people with diabetes in the RCTs we included are middle-aged and elderly people or working people.…”

Section: Discussionmentioning

confidence: 99%

Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis

et al. 2023

View full text Add to dashboard Cite

PurposeThis meta-analysis compared the long-term (12 months or 24 months) efficacy and safety of intravitreal aflibercept injection (IAI) for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR).MethodsWe selected 16 randomized controlled trials (RCTs) performed after 2015 that had a minimum of 12 months and up to 24 months of treatment and conducted a meta-analysis with Review Manager version 5.3. Visual acuity (VA), central subfield thickness (CST) and adverse events were the outcomes selected for evaluation from the eligible studies.ResultsBased on 16 RCTs, we evaluated a total of 7125 patients. For PDR and severe DME with poor baseline vision, after a minimum of 12 months and up to 24 months of treatment, the aflibercept treatment group obtained better VA improvement than the focal/grid laser photocoagulation treatment group (MD=13.30; 95%CI: 13.01~13.58; P<0.001) or other treatments (ranibizumab, focal/grid laser photocoagulation, PRP, et al.) group (MD=1.10; 95%CI: 1.05~1.16; P<0.001). In addition, the aflibercept treatment group got higher CST reduction than the focal/grid laser photocoagulation treatment (MD=-33.76; 95%CI: -45.53 ~ -21.99; P<0.001) or other treatments (ranibizumab, focal/grid laser photocoagulation, et al.) group (MD=-33.76; 95%CI: -45.53 ~ -21.99; P<0.001). There was no significant difference in the overall incidence of ocular and non-ocular adverse events in each treatment group.ConclusionsThis meta-analysis showed that the advantages of IAI are obvious in the management of DME and PDR with poor baseline vision for long-term observation (a minimum of 12 months and up to 24 months) with both VA improvement and CST reduction. Applied IAI separately trended to be more effective than panretinal photocoagulation separately in VA improvement for PDR. More parameters should be required to assess functional and anatomic outcomes.

show abstract

“…A cross-sectional study based on 13,473 diabetic patients complemented postprandial glucose, glycosylated hemoglobin (HbAlc), triglycerides, and low-density lipoprotein as independent risk factors for DR, with preprandial glucose, postprandial glucose, and HbAlc all being significant predictors of the development or progression of DR ( 33 ), which showed that each 1% increase in HbAlc was associated with a 40% increase in the risk of microvascular events ( 34 ). In addition, anemia ( 35 , 36 ), pregnancy ( 37 ), smoking ( 38 ), genetic factors ( 39 ), and microalbuminuria ( 40 , 41 ) have been shown in multiple trials to increase the risk of DR. Meta-analysis of multiple prospective cohort studies suggests that obesity is a risk factor for DR ( 42 , 43 ).…”

Section: Parallelism Between Dn and Dr Developmentmentioning

confidence: 99%

Parallelism and non-parallelism in diabetic nephropathy and diabetic retinopathy

Tang,

An,

Sun

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic nephropathy (DN) and diabetic retinopathy (DR), as microvascular complications of diabetes mellitus, are currently the leading causes of end-stage renal disease (ESRD) and blindness, respectively, in the adult working population, and they are major public health problems with social and economic burdens. The parallelism between the two in the process of occurrence and development manifests in the high overlap of disease-causing risk factors and pathogenesis, high rates of comorbidity, mutually predictive effects, and partial concordance in the clinical use of medications. However, since the two organs, the eye and the kidney, have their unique internal environment and physiological processes, each with specific influencing molecules, and the target organs have non-parallelism due to different pathological changes and responses to various influencing factors, this article provides an overview of the parallelism and non-parallelism between DN and DR to further recognize the commonalities and differences between the two diseases and provide references for early diagnosis, clinical guidance on the use of medication, and the development of new drugs.

show abstract

Relationship between diabetic retinopathy microalbuminuria and other modifiable risk factors

Cited by 9 publications

References 16 publications

RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022

RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022

Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis

Parallelism and non-parallelism in diabetic nephropathy and diabetic retinopathy

Contact Info

Product

Resources

About